2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow 17 alpha-Hydroxyprogesterone Caproate: new trials by email Literature Review of 17 alpha-Hydroxyprogesterone Caproate trials Research Report on 17 alpha-Hydroxyprogesterone Caproate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) - Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women | Phase 3 | Terminated | AMAG Pharmaceuticals, Inc. | 60 | 2016-10-07 | 2022-04-21 |
| RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix 17 alpha-hydroxyprogesterone caproate, Placebo Oil - Preterm Delivery, Cervical Length | Phase 3 | Terminated | The George Washington University Biostatistics Center | 657 | 2007-04-01 | 2019-07-15 |
Premature Birth (1)
AMAG Pharmaceuticals, Inc. (1) · The George Washington University Biostatistics Center (1)
United States (2)
Menachem Miodovnik, MD (1) · Neil Singla, MD (1) · William Grobman, MD, MBA (1)
U10HD021410 (1), U10HD027869 (1), U10HD027915 (1), U10HD027917 (1), U10HD034116 (1), U10HD034136 (1), U10HD034208 (1), U10HD036801 (1), U10HD040485 (1), U10HD040500 (1), U10HD040512 (1), U10HD040544 (1), U10HD040545 (1), U10HD040560 (1), U10HD053097 (1)